Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
NCT07133308
Recruiting
This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
08/13/2025
Locations: Total Skin And Beauty Dermatology Center, Birmingham, Alabama +21 locations
Conditions: Alopecia Areata
Register for Updates
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
NCT06985147
Recruiting
This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Mayo Clinic in Arizona, Phoenix, Arizona +4 locations
Conditions: Polycythemia Vera (PV)
Register for Updates
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721
Recruiting
The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/13/2025
Locations: Precision NextGen Oncology and Research Center, Beverly Hills, California +194 locations
Conditions: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Register for Updates
Breathwork Intervention for Posttraumatic Stress
NCT07129278
Recruiting
The goal of this single-site, single-arm pilot study is to examine the impact of breathwork training for posttraumatic stress symptoms in an adult veteran population. Participants will complete a single, in-person breathwork session (2 hours) led by a certified breathwork facilitator and engage in an integration session (30 minute) with a licensed psychologist. Participants will be invited to engage in two, optional, virtual follow up breathwork sessions (40 minute practice each) during weeks 2... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Diamond Rose Sanctuary, Branford, Connecticut +1 locations
Conditions: PTSD
Register for Updates
National Eye Institute Biorepository for Retinal Diseases
NCT01496625
Recruiting
Background: - To understand diseases of the retina and the eye, information is needed about people with and without such diseases. Researchers want to study these people and follow them over time. They also want to study body tissues and blood to understand the nature of eye disease. Studying genes, cells, and tissues may help them understand why some people get eye problems and others do not, or why some people respond to treatment while others do not. Researchers want to collect physical samp... Read More
Gender:
ALL
Ages:
Between 2 years and 120 years
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease, Retinal Vein Occlusion
Register for Updates
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT07096674
Recruiting
This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/13/2025
Locations: Site Number 1, Huntersville, North Carolina
Conditions: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Register for Updates
A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT06961006
Recruiting
Researchers want to learn if V940 with pembrolizumab can stop advanced melanoma from growing or spreading. Melanoma is a type of skin cancer. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. A standard (or usual) treatment for advanced melanoma is immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. V940 is a study treatment designed to help a person's immune system attack their specific cancer. Pembrolizumab is... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Highlands Oncology Group ( Site 4042), Springdale, Arkansas +7 locations
Conditions: Malignant Melanoma
Register for Updates
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
NCT06988618
Recruiting
The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Galderma Investigational Site # 8893, Birmingham, Alabama +50 locations
Conditions: Prurigo Nodularis
Register for Updates
Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression
NCT07127913
Recruiting
Neurons are specialized types of cells that are responsible for carrying out the functions of the brain. Neurons communicate with electrical signals. In diseases such as major depression this electrical communication can go awry. One way to change brain function is using electrical stimulation to help alter the communication between groups of neurons in the brain. The purpose of this study is to test a personalized approach to brain stimulation as an intervention for bipolar depression The stud... Read More
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
08/13/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Bipolar II Disorder, Bipolar II Disorder, Most Recent Episode Major Depressive
Register for Updates
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433
Recruiting
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
Gender:
ALL
Ages:
Between 45 years and 99 years
Trial Updated:
08/13/2025
Locations: Eastern Shore Research Institute, Fairhope, Alabama +76 locations
Conditions: Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Register for Updates
Methamphetamine and Troriluzole
NCT06989853
Recruiting
This will be a human laboratory study evaluating the influence of troriluzole treatment on the effects of methamphetamine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/13/2025
Locations: Psychopharmacology of Addiction Laboratory, Lexington, Kentucky
Conditions: Methamphetamine Use Disorder
Register for Updates
Collection of Data and Samples From Healthy Donors for Use in Translational Research
NCT00090662
Recruiting
Increased numbers of white blood cells called eosinophils can cause disease. To investigate this disease, researchers need blood, urine, sputum, stool, cerebrospinal fluid, skin and/or bone marrow samples to compare to samples from patients with this problem. Some of the samples will be used for genetic testing or future research. This study will last for about 10 years and will include a maximum of 50 paid volunteers ages 18 to 65.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy Volunteer
Register for Updates